Sleep and respiratory medicine products maker ResMed has introduced its Air Solutions range, including AirCurve 10 CS PaceWave with AirView system.

The new system is said to combine remote monitoring with firm’s PaceWave Minute Ventilation (MV)-Adaptive-Servo-Ventilation (ASV) therapy.

ResMed Europe and Asia Pacific president Anne Reiser said: "The launch of Air Solutions and the unique offering of the AirCurve 10 CS PaceWave with AirView represents a landmark shift in the treatment of central sleep apnoea.

"By combining ResMed-patented technology with new wireless monitoring capabilities, we are providing a solution that is both an effective therapy, and has potential to offer significant time and cost savings to physicians and health services."

Using the patented algorithm, PaceWave MV-ASV allows a patient’s breathing during sleep to be intelligently stabilised and monitored, providing an option to treat different patients with central sleep apnoea (CSA), a specific form of sleep-disordered breathing.

It is mostly suitable for patients suffering with Cheyne-Stokes Respiration (CSR), a pattern of CSA commonly oserved in heart failure patients.

According to the firm, the use of PaceWave MV-ASV therapy to treat CSA in patients with chronic heart failure is currently being investigated in SERVE-HF randomised trial.

The study, which completed 1,325 patients enrolment in 2013, has been designed to investigate if treating chronic heart failure patients who also have CSA with PaceWave MV-ASV therapy may improve outcomes including mortality and morbidity.

Currently, AirCurve 10 CS PaceWave is available for customers in select European countries.